



**Supplemental Table 1. Statistical analysis of growth delay of B16-OVA and parental B16F10 tumors during RFA + ACT**

<b>B16-OVA†</b>										
	Day 9	Day 11	Day 14	Day 16	Day 19	Day 21	Day 23	Day 26	Day 29	Day 33
RFA + ACT vs RFA	ns	ns	ns	**	**	**	**	**	#	#
RFA + ACT vs Sham + ACT	ns	ns	*	**	**	**	**	*	*	*
RFA + ACT vs Sham	ns	ns	**	**	**	#	#	#	#	#
RFA vs Sham + ACT	ns	ns	ns	ns	ns	ns	*	ns	#	#
RFA vs Sham	ns	ns	**	**	**	#	#	#	#	#
Sham + ACT vs Sham	ns	ns	ns	ns	**	#	#	#	#	#

<b>B16F10†</b>								
	Day 9	Day 11	Day 14	Day 16	Day 19	Day 21	Day 23	Day 26
RFA + ACT vs RFA	ns	ns	ns	ns	ns	ns	ns	ns
RFA + ACT vs Sham + ACT	ns	ns	**	**	**	#	#	#
RFA + ACT vs Sham	ns	ns	**	**	**	#	#	#
RFA vs Sham + ACT	ns	ns	**	**	**	#	#	#
RFA vs Sham	ns	ns	**	**	**	#	#	#
Sham + ACT vs Sham	ns	ns	ns	ns	ns	#	#	#

†Statistical comparisons of B16-OVA and B16F10 tumor volume between all treatment groups at all timepoints measured for data shown in Figure 6A. \* $P < 0.05$ ; \*\* $P < 0.01$  using Mann-Whitney U test; ns = not significant, # = comparison cannot be made as one group has been removed from the study.

**Supplemental Table 2. Statistical analysis of growth delay of CT26-HA tumors during RFA + ACT**

CT26-HA†										
	Day 9	Day 11	Day 15	Day 18	Day 21	Day 23	Day 25	Day 28	Day 32	Day 35
RFA + ACT vs RFA	ns	ns	ns	ns	*	**	*	**	**	*
RFA + ACT vs Sham + ACT	ns	ns	**	**	**	**	**	**	**	#
RFA + ACT vs Sham	ns	**	**	**	**	**	**	**	#	#
RFA vs Sham + ACT	ns	ns	**	**	**	**	**	**	*	#
RFA vs Sham	ns	**	**	**	**	**	**	**	#	#
Sham + ACT vs Sham	ns	**	ns	ns	ns	ns	ns	ns	#	#

†Statistical comparisons of CT26-HA tumor volume between all treatment groups at all timepoints measured for data shown in Figure 6B. \* $P < 0.05$ ; \*\* $P < 0.01$  using Mann-Whitney U test; ns = not significant, # = comparison cannot be made as one group has been removed from the study.